When people with HIV and belly fat lost fat from a placebo pill, their liver enzymes didn't improve, but when they lost fat from tesamorelin, their liver enzymes did improve.

For people with HIV and belly fat who have high liver enzyme levels, those who lost at least 8% of their visceral fat from the drug had much bigger drops in their liver enzyme numbers compared to those who didn't lose much fat, and this difference was statistically significant.

HIV patients with belly fat and high liver enzymes who lost at least 8% of their visceral fat from the drug saw their ALT drop by about 9 points (18%) and AST by 4 points (10%) after six months of treatment.

For HIV patients with belly fat and high liver enzymes, taking a placebo even if they lost visceral fat didn't help lower their liver enzyme levels, unlike those taking the actual drug.

Even after stopping tesamorelin and some fat coming back, the liver enzyme improvements stayed for a year in patients who initially lost visceral fat.

In HIV patients with belly fat, higher amounts of visceral fat were linked to higher liver enzyme levels at the start of the study.